Mgi Pharma Inc

Mgi Pharma — Guilford Pharmaceuticals — Merger or Acquisition (July 2005)

16 slides from Mgi Pharma's merger presentation, Jul 29, 2005

  1. Slide 1: Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company

    Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company Banc of America July 29, 2005

  2. Slide 2: Additional Information And Where To Find It

    Additional Information And Where To Find It MGI PHARMA intends to file a registration statement on Form S-4 containing a proxy statement/prospectus in connection with the proposed acquisition of Guilford by MGI PHARMA pursuant to the terms of the Agreement and Plan of Merger by and between MGI PHARM

  3. Slide 3: MGI PHARMA: Building A Leading Biopharmaceutical Company

    MGI PHARMA Building A Leading Biopharmaceutical Company Revenue potential >$1B within 5 years Aloxi® injection 1H05 sales of $118 M #1 share position in IV 5-HT3 CINV market Product portfolio expansion Pending acquisition of Guilford Pharmaceuticals Aquavan® pivotal program to begin (procedural seda

  4. Slide 4: Guilford Pharmaceuticals: Strategic Rationale

    MGI PHARMA Guilford Pharmaceuticals: Strategic Rationale Complimentary Franchises in Oncology & Acute Care Aquavan® Injection Compliments Aloxi® for PONV >$250 million U.S. revenue potential Pivotal program planning underway Gliadel® Wafer Fits current oncology focus 2004 sales totaled $27.7M Augmen

  5. Slide 5: A Leading Biopharmaceutical Company

    MGI PHARMA A Leading Biopharmaceutical Company Marketed products Clinical development pipeline Dacogen™ injection (MDS, AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation Aquavan® injection (procedural sedation) ZYC101a (cervical dysplasia) Irofulven (HR

  6. Slide 6: The Best in Class 5-HT3 Antagonist for CINV

    The Best in Class 5-HT3 Antagonist for CINV Approved for both acute and delayed chemotherapy-induced nausea & vomiting (CINV) Favorable head-to-head trials vs. competitive agents 1H05 sales of $118 million #1 share position in IV CINV market Franchise expansion includes postoperative nausea & vomiti

  7. Slide 7: Post Operative Nausea & Vomiting (PONV)

    Post Operative Nausea & Vomiting (PONV) PONV is common with anesthesia and surgical procedures Prevalent in gynecological, abdominal, and ear, nose and throat surgeries Incidence of PONV estimated at 25% to 30% ~ 30 million doses of 5-HT3 RAs used annually in U.S. for PONV Can delay hospital dischar

  8. Slide 8: A Leading Biopharmaceutical Company

    MGI PHARMA A Leading Biopharmaceutical Company Marketed products Clinical development pipeline Dacogen™ injection (MDS, AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation Aquavan® injection (procedural sedation) ZYC101a (cervical dysplasia) Irofulven (HR

  9. Slide 9: Anti-Cancer Agent with Broad Clinical Activity

    Anti-Cancer Agent with Broad Clinical Activity Myelodysplastic syndromes (MDS) MAA accepted for review by EMEA NDA accepted for review by FDA; Sept. 1 PDUFA date Alternative dosing regimen studies ongoing Phase 2 acute myeloid leukemia (AML) trial in elderly patients underway and phase 3 AML trial e

  10. Slide 10: Supportive Care Agent for Oral Mucositis

    Supportive Care Agent for Oral Mucositis Proprietary oral formulation (Up-Tec™) of L-glutamine Pivotal phase 3 trial complete in breast cancer patients Primary endpoint met (p=0.026): overall 22% risk reduction (WHO?2) vs. placebo Significant activity in prevention of WHO grade 3 mucositis NDA filin

  11. Slide 11: ZYC101a: Immunotherapeutic for Cervical Dysplasia

    ZYC101a Immunotherapeutic for Cervical Dysplasia Immune response therapeutic for treatment of cervical dysplasia, a precancerous condition Phase 2 study completed in 161 patients: In a prospectively defined population of patients under age 25, resolution of high grade dysplasia observed in 70% vs. 2

  12. Slide 12: Irofulven: A Novel, Broadly Active Cytotoxic

    Irofulven A Novel, Broadly Active Cytotoxic New chemotherapeutic class with a novel mechanism of action Monotherapy activity in prostate, liver, ovarian and pancreatic cancers Combination activity in prostate, colorectal and thyroid cancers Strong patent position and exclusive worldwide rights Multi

  13. Slide 13: 2005 Financial Guidance

    2005 Financial Guidance Provided July 21, 2005 Excluding any impact of the GLFD transaction: Total revenues of $285 million Aloxi sales of $260 million Other product sales, promotion and licensing revenue of $25 million COGS of $97 million SG&A of $80 million Net R&D of $46 million Operating income

  14. Slide 14: Balance Sheet

    Balance Sheet (In Thousands) June 30, 2005 ACTUAL Cash and Unrestricted Marketable Investments1 $218,845 Total Assets $439,519 Long-term Debt $260,172 Total Shareholders’ Equity $138,090 Shares Outstanding2 75,703 1. Excludes equity investments 2. Excludes approx. 8 million shares that could issue u

  15. Slide 15: Goals for 2005

    Goals for 2005 Revenue: Achieve U.S. sales of Aloxi injection of $260 million Achieve other product sales, promotion and licensing revenue of $25 million Product candidates: Complete pre-launch activities for Dacogen injection for MDS and obtain regulatory approvals Advance the Dacogen injection dev

  16. Slide 16: Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company

    Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company Banc of America July 29, 2005

Guilford Pharmaceuticals — Merger or Acquisition (July 2005) on 6ix